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ABSTRACT 
Endogenous retrotransposon sequences constitute approximately 42% of the human genome and 
mobilisation of retrotransposons has resulted in rearrangements, duplications, deletions, novel 
transcripts and the introduction of new regulatory domains throughout the human genome. Both 
germline and somatic de novo retrotransposition events have been involved in a range of human 
diseases and there is emerging evidence for the modulation of retrotransposon activity during the 
development of specific diseases. Particularly, there is unequivocal consensus, that endogenous 
retrotransposition can occur in neuronal lineages. This review addresses our current knowledge of 
the different mechanisms through which retrotransposons might influence the development of and 
predisposition to ALS.  
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterised by the 
rapid progressive degeneration of upper and lower motor neurons. This results in the wasting and 
weakening of muscles of the limbs and trunk and those involved in speaking, swallowing and facial 
expression. It is usually fatal within 3-5 years of disease onset, most frequently due to respiratory 
failure.
1
 In European populations, the incidence of ALS is 2.16 per 100,000 people per year and the 
median age at diagnosis is 65.2 and 67 years for men and women respectively.
2
 The mechanisms 
underlying the pathogenesis of ALS are not fully understood, however there have been several 
hypotheses proposed to explain what drives the development of the disease, which include protein 
aggregation, oxidative stress, excitotoxicity and defects in RNA processing and axonal transport.
3
 5-
10% of cases of ALS are reported as familial and the remaining as sporadic. However, this division 
may not accurately reflect the mechanisms and risk associated with disease development.
S1
 Familial 
ALS is defined by a positive family history of the disease but family history may not always be 
apparent, has varying definitions and many of the mutations identified in cases of familial ALS are 
also found in those with the sporadic form.
4
 
S2
 Twin studies estimate a heritability of 60% in sporadic 
ALS and first degree relatives of sporadic ALS patients have an eight-fold increased risk of developing 
the disease demonstrating further the importance of genetics in the sporadic disease.
S3 S4
 There have 
been more than 30 genes associated with familial and sporadic ALS and more genetic risk loci 
identified through genome wide association studies (GWAS).
5 6
 The four genes harbouring mutations 
that cause the greatest number of ALS cases are SOD1, C9orf72, FUS and TARDBP, contributing to 
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47.7% and 5.2% of familial and sporadic cases, respectively, in a recent meta-analysis of European 
and Asian populations.
7
  
The increase in the generation and availability of sequencing data has driven the discovery of new 
genes involved in the development of ALS, with the rate of discovery doubling every four years.
S5
 
Despite these findings there is still much to learn about the genetic causes of ALS and how variants 
affect disease progression. The same mutation in different individuals does not always result in the 
same clinical progression or even the same disease. The C9orf72 repeat expansion and mutations in 
FUS and TARDBP can lead either to the development of ALS or frontotemporal lobar degeneration 
(FTLD).
8
 Additional modifying genetic variants and environmental factors or a combination of both 
are likely to contribute to the phenotypic heterogeneity seen in carriers of these mutations. For 
example, the intermediate length trinucleotide CAG repeats encoding polyglutamine tracts in the 
ATXN2 gene that confer a risk of developing ALS, have been associated with C9orf72 repeat 
expansion carriers with ALS but not with those carriers with FTLD.
9 10
 Environmental factors have 
also been implicated in ALS pathogenesis, but it has proven difficult to replicate these experimental 
outcomes reliably. Proposed environmental risk factors include physical exercise and exposure to 
heavy metals, pesticides and electromagnetic radiation.
5 11
 Modelling of the population with ALS 
suggest ALS development is a multistep process requiring six molecular steps, and these are likely to 
be a combination of genetic and environmental factors.
12
 
One component of the human genome that has been largely overlooked in conjunction with 
neurodegenerative diseases until recently is the group of endogenous transposable elements (TEs), 
even though such structures contribute to nearly half of our genome. Their role in evolution, 
disease, regulation of gene expression, response to environmental stimuli, and their ability to 
generate genetic diversity both within a population and within an individual have led to them no 
longer being considered ‘junk’ DNA but an important part of the human genome.
13-15
 Two classes of 
TEs can be identified in mammalian genomes: 
1) DNA transposons are widely represented in different taxa of organisms including 
vertebrates. Functional transposons encode a transposase protein, flanked by two terminal 
inverted repeats (TIRs) (Figure 1A) and move by a ‘cut-and-paste’ mechanism that involves 
excising an element and its reinsertion at a new genomic location.
S6
 Upon insertion, a 
sequence in the target site is duplicated generating a target site duplication (TSD).
S7
 DNA 
transposon sequences account for around 3% of the human genome but, with the exception 
of at least one family of PiggBac elements in little brown bats
S8
, no functional DNA 
transposons have been identified in mammals to date.    
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2)    Retrotransposons comprise approximately 42% of the human genome and propagate via a 
‘copy-and-paste’ mechanism, meaning that retrotransposon transcripts are reverse 
transcribed into a cDNA intermediate which is integrated into a new site of the host genome 
by retrotransposon-encoded proteins. Retrotransposons can be subdivided into long 
terminal repeat (LTR) retrotransposons and non-LTR retrotransposons (Figure 1B).
16
 This 
review will bring retrotransposons into sharper focus and discuss how their activity could 
contribute to the development and progression of ALS. 
 
LTR RETROTRANSPOSONS 
Human endogenous retroviruses (HERVs) belong to the class of LTR retrotransposons that constitute 
approximately 8% of the human genome. They are flanked by LTRs which contain transcriptional 
regulatory domains controlling expression of the proviral DNA but have also been exapted as 
regulatory elements for endogenous genes (Figure 2).
 S9 S10
 Endogenous retroviruses resulted from 
the repeated infection of germ cells by exogenous retroviruses and became unable to re-infect due 
to mutations that accumulated in their proviral DNA.
17
 As a consequence, expression of endogenous 
retrovirus proviral DNA does not lead to infectious particles and there is currently no evidence that 
endogenous retroviruses still mobilise in humans although this cannot be ruled out.
17 18
 The 
classification of HERVs is complex and dependant on the methodology used with HERVs divided into 
50-200 families.
19
 One of the methods is primarily based on the tRNA that binds to the viral primer 
binding site which for HERV-K is the lysine (K) tRNA and the most recent inherited proviral insertions 
in the human genome are HERV-K sequences.
17
 A complete autonomous HERV-K sequence harbours 
7-9kb of DNA coding for the viral proteins gag, pro, pol and env, and is flanked by ∼1000bp LTRs 
(Figure 1B). There are a small number of complete HERV-K elements in the human genome, however 
the majority of HERV families no longer encode functional proteins, and in many cases, the only 
remnant of the HERV integration is a solo LTR due to the removal of the originally LTR-flanked region 
by recombination events. HERV-K insertions are present in Old World monkeys, apes and humans 
and are likely to have entered the primate lineage after the divergence of New and Old World 
monkeys.
S11
 Similarities in sequence allow for the identification of 10 HERV-K families (HML-1 to 
HML-10) and a number of HML-2 loci, the youngest family, are human specific indicating their 
continued mobilisation during human evolution.
18
 Recent reports have also identified polymorphic 
HERV-K insertions for their presence/absence in humans
20
 suggesting recent mobilisation activity 
and the possibility that some HERV-K copies might currently still retain the capability to mobilise in 
present-day humans. Multiple neurological diseases, including multiple sclerosis, schizophrenia and 
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ALS, have been associated with HERVs and HERV-K is the predominant family studied in the 
pathogenesis of ALS but as yet a direct cause-effect relationship has yet to proven.
21
 
S12 
 
NON-LTR RETROTRANSPOSONS 
Non-LTR retrotransposons lack LTRs, include the families of long interspersed nuclear element-1 
(LINE-1/L1), short interspersed nuclear elements (SINEs) and SINE-VNTR-Alu (SVA) retrotransposons 
(Figure 1B) and represent the only group of TEs that is still currently mobilised in the human 
genome.
16
 The LINE-1 subfamily represents the only autonomous group of human non-LTRs because 
members of this subfamily encode those proteins that are essential for their mobilisation and there 
are 80-100 retrotransposition competent LINE-1 elements in the human reference genome.
22
 A 
functional, full length LINE-1 element is ~6kb in length, contains a 5’ and 3’-untranslated region 
(UTR), three open reading frames (ORF0, ORF1, ORF2) whereby ORF1 and ORF2 are separated by a 
63bp spacer region, a poly A tail at its 3’end and is flanked by variable length target site duplications 
(TSDs) (Figure 1B). The 5’ UTR includes a sense and antisense promoter. ORF1p is a ~40 kDa protein 
with RNA binding and chaperone activities.
S13
 ORF2p has a molecular weight of ~150 kDa and 
harbours endonuclease (EN) 
S14
 and reverse transcriptase (RT) activities 
23
 (Figure 1B). Both ORF1p 
and ORF2p are essential for retrotransposition of their own mRNA in cis which is performed by a 
mechanism termed target primed reverse transcription (TPRT) (Figure 3). This mechanism involves 
the nicking of the bottom strand of the target DNA by the endonuclease domain of ORF2p to expose 
a 3’hydroxyl for priming reverse transcription of LINE-1 mRNA by the reverse transcriptase domain 
of ORF2p.
S15
 Due to the presence of a conserved antisense promoter in full-length LINE-1 elements 
S16
, a third ORF named ORF0 has recently been identified in selected human LINE-1 elements with 
ORF0p enhancing their retrotransposition.
S17
 The non-autonomous non-LTR retrotransposons Alu 
and SVA do not have any protein-coding capacity and recruit the LINE-1 protein machinery for their 
own mobilisation in trans. Alu elements are primate-specific short interspersed nuclear elements 
derived from the 7SL RNA gene and there are approximately 1.5 million copies in the human genome 
(Figure 1B).
24
 SVAs are hominid specific composite elements consisting of a 5’ hexamer repeat that 
can be variable in length ((CCCTCT)n), two Alu fragments in antisense orientation, a GC-rich variable 
number tandem repeat (VNTR), a SINE-R sequence derived from a HERV-K10 element and a poly A-
tail following a polyadenylation signal (Figure 1B).
25
 The continuing expansion of non-LTR 
retrotransposons has contributed to more than a third of the human genome shaping its 
organisation and gene expression through a variety of mechanisms including insertional 
mutagenesis, deletions at the insertion site, 5’- and 3’ transductions, non-allelic homologous 
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recombination, transcript pausing or termination, antisense/sense promoter effects, alternative 
splicing, heterochromatisation and processed pseudogene formation.
13 16
 Furthermore, non-LTR 
retrotransposon insertions can affect host gene expression by numerous mechanisms (Figure 4). 
It is well established that new LINE-1, Alu and SVA mobilisation events occur in most instances 
during early embryogenesis and to some extent in germ cells.
26
 The neuronal lineages in 
hippocampus, cerebellum, caudate nucleus and cortex (reviewed in 
26
) support mobilisation of 
human endogenous LINE-1 elements and LINE-1 mediated insertions occur throughout fetal and 
adult neurogenesis as well as in mature neurons resulting in somatic mosaicism in the adult brain.
27-
31
 LINE-1 retrotransposition has also been demonstrated in tumour cells resulting in somatically 
acquired insertions in cancer genomes (reviewed in 
S18
). De novo retrotransposition events that 
occur in germ cells and during early embryonic development prior to partitioning of the germline are 
heritable and create genetic variation in the population, whereas those occurring in somatic tissues 
will not be passed on to the next generation but could influence cellular function and fitness of the 
individual.  
 
DETECTION OF REVERSE TRANSCRITPASE ACTIVITY IN ALS PATIENTS 
It has been hypothesised retroviral activity may, at least in part, be involved in ALS development.
32
 
Evidence for this hypothesis includes motor neuron dysfunction in mice caused by a retroviral 
infection, the identification of antibodies in the sera of ALS patients directed against retroviral 
proteins of the human T-lymphotrophic virus and the development of ALS-like syndromes in patients 
infected with the human T-lymphotrophic virus-1 and human immunodeficiency virus (HIV).
32
 
S19 S20
 
Also, patients with HIV-associated ALS syndromes may experience improvement in such symptoms 
with antiretroviral treatment.
33 34
 Both retroviruses and autonomous retrotransposons encode a 
reverse transcriptase (RT) enzyme generating a cDNA copy of the proviral and retrotransposon-
encoded mRNA, respectively.
17 23
 RT activity was detected in 59% of sera from ALS patients but only 
in 5% of sera from an unaffected control group, but it could not be attributed to the presence of any 
known human exogenous retrovirus.
35
 A second study also detected a significant difference in RT 
activity in the sera of ALS patients compared to non–blood relative controls (spouses and healthy 
volunteers) (47% vs 18%), however there was only a small difference in RT activity when comparing 
the ALS patients to blood relative controls (first degree, aunt or cousin) (47% vs 43%).
36
 Comparable 
levels of RT activity in blood relative controls of ALS patients and the absence of any detectable 
exogenous retrovirus suggests that the origin of the RT activity is endogenous. A recent study 
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demonstrating the activation of an endogenous retrovirus in at least a subpopulation of sporadic ALS 
patients 
37
 suggests that this endogenous RT is at least one source of the detected RT activity. 
Determining any potential role of RT in the pathogenesis of the disease is hugely important to 
improve our understanding of the development of ALS. If the increase in RT activity in ALS was 
shown to have a causative role in the pathogenesis of the disease, well-established RT inhibitors may 
provide a viable target for treatment. 
 
GLOBAL CHANGES TO TRANSPOSABLE ELEMENT REGULATION IN ALS 
There is evidence for a global activation of TEs in ALS, that includes both LTR and non-LTR 
retrotransposons, and TEs belonging to both retrotransposon and DNA transposon classes are 
regulated by TAR DNA-binding protein 43 (TDP-43), a protein involved in neurodegenerative 
disorders including ALS, FTLD and Alzheimer’s disease.
8
 
S21
 As previously stated, mutations in the 
TARDBP gene encoding the TDP-43 protein have been identified in both familial and sporadic cases 
of ALS and FTLD.
7
 Moreover, the accumulation of TDP-43 in the cytoplasm occurs in the majority of 
ALS and 45-60% of FTLD cases.
S22 S23
 TDP-43 is a nucleic acid binding protein with distinct binding 
affinities for RNA and DNA and is involved in the regulation of transcription and splicing, miRNA 
processing and the stability and transport of mRNA.
 S24
 One study found that transcripts derived 
from LTR and non-LTR retrotransposons and DNA transposons are targets of TDP-43 in humans, rats 
and mice and that this association of TDP-43 and TE transcripts is decreased in the brain tissue of 
FTLD patients compared to controls.
38
 This study also demonstrated that in two different mouse 
models of TDP-43 dysfunction (overexpression and striatal depletion), TE transcripts were 
overexpressed; the authors hypothesised that TE overexpression may be part of TDP-43 pathology 
and contribute to TDP-43 related neurodegeneration. Another model system of ALS using Drosophila 
melanogaster in which the expression of human TDP-43 in either neurons or glia resulted in protein 
aggregation, motor impairment and premature death was used to investigate the relationship of 
TDP-43 and TEs further.
39
 Human TDP-43 overexpression was found to be correlated with elevated 
expression of members of the class of LTR retrotransposons and LINE families in Drosophila due to 
the loss of small interfering RNAs that act post transcriptionally to repress these elements. Further, 
they found that the expression of human TDP-43 and activation of retrotransposon expression 
caused cell death through DNA damage-mediated signalling. It was shown that this type of toxicity in 
glial cells was due to the activity of the endogenous retrovirus gypsy as the phenotype could be 
rescued when gypsy expression was inhibited either genetically or pharmacologically (reverse 
transcriptase inhibitors). The data suggests that the activation of retrotransposons could be 
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contributing to TDP-43 mediated neurodegeneration, which includes ALS and FTLD. Similarly, a study 
analysing the transcriptome of the frontal cortex and cerebellum of ALS patients demonstrating 
C9orf72 GGGGCC repeat expansions identified a significant increase in transcripts from both classes 
of TEs (retrotransposons and DNA transposons) in the frontal cortex when compared to controls.
40
 
Although C9orf72 expansion-negative ALS patients also demonstrated a similar trend of increased TE 
expression in the frontal cortex, this was not statistically significant. The study did not find an 
association either between TDP-43 levels or pathology and the increase in TE transcripts, however 
the changes observed positively correlated with RNA polymerase II activity. The data suggests that 
there was a global change in TE expression and activity in the brains of certain ALS patients and the 
exact role, if any, of the different TE families in disease progression is still to be determined. Table 1 
summarises the finding from these studies linking TE expression to ALS and FTLD. In addition, several 
other neurological diseases have been associated with retrotransposon activity, more specifically 
LINE-1, including Rett Syndrome, Ataxia Telangiectasia, autism and schizophrenia 
S25-S29
 and 
therefore the dysregulation of retrotransposons may not only be part of the ALS disease process but 
also play a wider role in neurological conditions. 
 
ACTIVATION OF ENDOGENOUS RETROVIRAL EXPRESSION IN ALS  
Several studies have been carried out, outlined below, implicating a role of HERV-K derived gene 
products in the pathogenesis of ALS. There is a significant increase in HERV-K pol expression in 
cortical brain tissue from ALS patients compared to non-ALS controls.
41
 HERV-K pol levels from the 
HML-2 and HML-3 subfamilies differ across brain regions in ALS patients but not in the non-ALS 
controls as do the genomic loci where the transcripts originate, suggesting unique patterns of 
expression in the brains of those with ALS. Immunohistochemistry shows the presence of HERV-K RT 
protein is limited to neurons and at significantly higher levels in ALS patients than in controls.
41
 In a 
subsequent study, transcripts of the gag, pol and env HERV-K genes were elevated in brain tissue 
from ALS patients over controls and expression of the HERV-K HML-2 Env protein was detected in 
cortical and spinal neurons of ALS patients but not in normal or Alzheimer’s disease brain tissue.
37
 
Although this provides evidence for the presence of HERV-K expression in ALS, it is not clear if this is 
part of the pathogenic process or a consequence of it. To elucidate the potential role of HERV-K in 
the pathogenesis of ALS, a transgenic mouse line expressing the HERV-K HML-2 Env protein in 
neurons has been generated.
37
 The transgenic animals develop progressive motor neuron 
degeneration involving both upper and lower motor neurons, atrophy of the motor cortex, DNA 
damage and morphological abnormalities of the neurons resulting in a 50% mortality rate by 10 
Page 8 of 27
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
9 
 
months, suggesting that HERV-K expression is cause rather than consequence. Additionally, 
transfection of the HERV-K HML-2 genome or HERV-K HML-2 env gene alone into human neuronal 
cells causes a decrease in cell number and retraction of neurites.
37
 In contrast to the above studies a 
recent report did not detect any compelling differences in the transcription of HERV-K HML-2 loci in 
ALS versus control brain and spinal cord samples and was unable to confirm the presence of full 
length HML-2 Env protein in ALS and control samples.
42
 Table 1 summarises the data from the above 
studies. 
A recent report on 5 HIV patients with motor neuron disease analysed the HERV-K RNA expression 
level in response to antiretroviral therapy.
33
 Data on HERV-K RNA levels at the onset of neurological 
symptoms were available for 2 patients who showed elevated HERV-K expression levels in plasma 
that became undetectable after treatment with antiretroviral therapy.
33
 HIV-1 infection is known to 
induce HERV-K expression, so it is unclear whether the antiretroviral therapy directly inhibits HERV-K 
or the reduction in HERV-K RNA is due to a loss of activation by HIV-1.
S30
 Clinical trials are currently 
underway testing the ability of antiretroviral therapy to suppress HERV-K expression and the safety 
and tolerability of these drugs in ALS patients (NCT02437110, NCT02868580 and Motor Neuron 
Disease Australia’s The Lighthouse Project). The results of these trials will be important in 
determining if the potentially pathogenic expression of this element could be modified with existing 
drugs.  
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Table 1: Summary of studies linking TE activity to ALS and FTLD. 
Study 
Transposable 
Element 
Cell Line and Animals Models Human Samples 
Andrews et al 
2000 
- - 
-Reverse transcriptase activity was detected using a product enhanced reverse 
transcriptase assay in the sera of a significantly higher number of motor neuron 
disease patients than controls (56% vs 5%). 
Steele et al 
2005 
- - 
-Using a product enhanced reverse transcriptase assay serum reverse 
transcriptase activity was detected in a higher proportion of sporadic ALS 
patients (47%) compared to unrelated controls (18%) but not compared to 
blood relatives of ALS patients (43%). 
Douville et al 
2011 
LTR 
retrotransposon 
(HERV-K) 
- 
-HERV-K pol transcript expression was significantly increased in the brains of ALS 
patients compared to controls as was neuronal HERV-K reverse transcriptase 
protein expression. 
-Specific genomic loci from which the HERV-K transcripts originated were 
identified and included a locus unique to the ALS samples. 
- In ALS brain tissue reverse transcriptase expression was positively correlated 
with TDP-43 and the reverse transcriptase protein colocalised with TDP-43. 
Li et al 2012 
 
 LTR and non-LTR 
retrotransposons 
and DNA 
transposons  
-TE transcripts are targeted by TDP-43 in both rats and mice. 
-TE transcripts are overexpressed in two different models of TDP-43 
dysfunction (overexpression of human TDP-43 in transgenic mice and 
depletion of TDP-43 in mice striatum). 
-TDP-43 targets TE transcripts in the human brain and this binding is 
significantly reduced in FTLD brain tissue compared to healthy. 
Li et al 2015 
LTR 
retrotransposon 
(HERV-K) 
-The expression of the HERV-K Env protein in human neurons caused a 
decrease in cell number and retraction of neurites and could contribute 
to neurotoxcity.  
-HERV-K expression was activated in human neurons upon the 
transfection of TDP-43 and TDP-43 was shown to bind to the LTR of the 
HERV-K. 
-Transgenic mice expressing HERV-K env gene in neurons showed a 
specific loss of upper and lower motor neurons, neuronal DNA damage 
and motor dysfunction.  
-Expression of the HERV-K gag, pol and env transcripts and the Env protein were 
detected in cortical and spinal neurons of ALS patients but not in those of 
healthy controls. 
Krug et al 
2017 
LTR and non-LTR 
retrotransposons 
-Neuronal and glial overexpression of human TDP-43 in Drosophila 
resulted in a loss of small interfering RNAs that repress retrotransposon 
expression and therefore levels of both LTR and non-LTR 
- 
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retrotransposons were elevated. 
- The toxicity associated with the overexpression of the gypsy ERV 
element was recused by either blocking its expression or by using 
reverse transcriptase inhibiters. 
Prudencio et 
al 2017 
LTR and non-LTR 
retrotransposons 
and DNA 
transposons 
- 
-TE expression was significantly increased in the frontal cortex of C9orf72 
positive ALS patients compared to who were C9orf72 negative and to healthy 
controls. 
-The increase in expression of TE transcripts was not positively correlated with 
TDP-43 transcript levels or those of phosphorylated TDP-43.  
Mayer et al 
2018 
LTR 
retrotransposon 
(HERV-K) 
- 
-HERV-K transcript levels were detected at relatively high levels from 24 
different loci across brain and spinal cord samples and no significant difference 
was observed between the ALS and controls. 
-In addition full length Env protein could not be detected in the ALS and controls 
samples, however there was data to indicate the presence of truncated protein 
variants in the ALS samples. 
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GERMLINE RETROTRANSPOSON INSERTION POLYMORPHISMS 
De novo retrotransposition events are detectable in approximately 1/20 live births for Alu elements, 
1/150 for LINE-1 and 1/1000 for SVA elements and within the global human population there are an 
estimated 392 million private insertions unique to those harbouring them.
14
 It is estimated that 
every human has on average 180 LINE-1, 1283 Alu and 56 SVA presence/absence insertion 
polymorphisms 
43
, which are an important source of genetic variation. The genetic variation 
generated by the presence or absence of these retrotransposons are termed retrotransposon 
insertion polymorphisms (RIPs). Due to the complex nature of the analysis, this type of genetic 
variation is not routinely studied in large cohorts although there is a wide range of bioinformatics 
tools available to analyse such variation.
44
 To date, no actively retrotransposing HERV elements have 
been reported to be able to create new insertions in the human genome. However, 36 polymorphic 
HERV-K insertions have been identified that are not present in the human reference genome in a 
study analysing over 2500 genomes.
20
 The few polymorphic HERV-K insertions are therefore a much 
smaller source of genetic variation compared to the huge number of polymorphic non-LTR 
retrotransposon insertions. To date, 124 LINE-1 mediated insertions have been identified as the 
genetic cause of diseases such as hereditary cancer, haemophilia, X-linked dystonia parkinsonism 
and neurofibromatosis type 1.
15
  Mechanisms by which the LINE-1-mediated de novo 
retrotransposition events affect the respective disease-related host genes include gene inactivation 
through aberrant splicing and exonic insertions causing frameshifts, deletions at the site of insertion 
and also the incorporation of the element’s sequence into the host protein affecting its function.
15
 
Many of these disease causing events are rare insertions resulting in a robust phenotype, but there 
are also more common RIPs that have been shown to affect the function of the gene they have 
inserted into. For example, an SVA-E insertion into intron 8 of the CASP8 gene is associated with 
transcript abnormalities and with an increased risk of breast cancer but a decreased risk of prostate 
cancer.
45
 There is also evidence for common Alu RIPs as candidate causative variants in diseases such 
as multiple sclerosis when identified to be in linkage disequilibrium with trait associated single 
nucleotide polymorphisms (SNPs) identified through GWAS.
46
 A study into the impact of RIPs on 
human health and disease through changes in gene expression, included a global analysis of LINE-1, 
Alu and SVA RIPs in linkage disequilibrium with SNPs associated with complex diseases from GWAS, 
found 2474 such elements in a European population.
47
 This study, using a focus on the human 
immune system, identified candidate RIPs that could lead to disease through changes in gene 
regulation.
47
 LINE-1 RIPs have also been shown to be enriched in intragenic regions and different 
gene ontologies and pathways when those found in controls were compared to individuals with 
schizophrenia.
S29
 Analysis of SNP variation demonstrated there is a 14.3% genetic correlation 
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between ALS and schizophrenia suggesting convergent biological mechanisms between the two 
diseases.
S31
 The burden of RIPs within an individual will vary and therefore the genes and pathways 
affected by their presence could also differ. 
There is data available on those RIPs that have already been identified, collated in a review 
44
 and in 
databases such as the European database of L1-HS retrotransposon insertion in humans 
(euL1db.unice.fr). There have also been large scale studies addressing RIPs in the 1000 genomes 
data.
S32
 So far, this list comprises approximately 40000 Alu, LINE-1 and SVA RIPs in the human 
populations studied but it will grow as further genomes are analysed. This list of RIPs includes 
several that are present in genes and genetic loci that are associated with ALS. It is possible that 
these retrotransposon insertions affect splicing and expression of the gene where they inserted 
through the introduction of novel splice sites and regulatory domains (Figure 4 for major 
mechanisms).
15 47
 We propose that these RIPs and others that have yet to be identified have the 
potential to alter the function or expression of the genes they have inserted into and could act as 
genetic predisposing factors for ALS.  Extensive analysis of those pathways containing genes 
potentially affected by RIPs is beyond the scope of a review. However as an example the NEK1 locus, 
a gene recently identified to contain risk variants for ALS and involved in mitochondrial function and 
DNA damage response
48
, has both reference non-LTR insertions and RIPs that could impact on the 
regulation and function of this gene. To explore this hypothesis, RIPs would need to be addressed in 
ALS patients and controls to determine if there are insertions that occur more frequently in one 
population compared to the other. The functional consequences of any insertions identified that are 
associated with disease risk would need to be investigated further. One such experiment could 
involve developing a cell culture model of induced pluripotent stem cells from patients harbouring 
the insertion, which could then be removed using CRISPR to evaluate the consequences of the 
specific insertion on host gene expression.  
 
SOMATIC MOBILISATION OF NON-LTR RETROTRANSPOSONS IN THE BRAIN 
Non-LTR retrotransposons can affect cellular function through insertions in the germline but also via 
their mobilisation in adult tissues, which includes neuronal cells. The evidence for the mobilisation of 
non-LTR retrotransposons in neuronal cells has come from a combination of studies using cell lines, 
animal models and human tissue. By applying engineered LINE-1 retrotransposition reporter 
elements in cell culture assays, it was demonstrated that rat neuronal progenitor cells, human fetal 
brain neuronal progenitor cells, neuronal progenitor cells derived from human embryonic stem cells 
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and mature non-dividing neurons can support human LINE-1 retrotransposition in vitro.
28-30
 In 
addition, an enhanced green fluorescent protein marked human LINE-1 retrotransposition reporter 
transgene in mice resulted in somatic mosaicism in the brain.
30
 A quantitative multiplexed PCR assay 
to determine the endogenous LINE-1 copy number in a given genome, demonstrates that there is an 
increase in LINE-1 copies in several brain regions compared to the heart and liver from the same 
human individual with the highest number found in the hippocampus.
28
 Using a novel technique 
termed retrotransposon capture sequencing, the identification and characterisation of endogenous 
somatic retrotransposition events in the human brain were characterised.
49 50
 Retrotransposon 
capture sequencing was used to generate libraries of retrotransposon insertions in genomic DNA 
from the hippocampus and caudate nucleus of three donors of advanced age (average 92 years old). 
Subsequent next generation sequencing identified 7,743 LINE-1, 13,692 Alu and 1,350 SVA putative 
somatic de novo insertions in total in the three individuals which were present in one brain region 
but absent in the other and not previously identified as a germline variant.
49
 33 of these potential de 
novo insertions were chosen for validation by genotyping PCR and capillary sequencing of the 
resulting PCR products successfully validating 28 of them as somatic de novo insertions that were 
absent from the second brain region.
49
 The number of neurons affected by an individual somatic de 
novo insertion would be dependent on the point in time of the retrotransposition event, whether it 
occurred in a single mature post-mitotic neuron, during neurogenesis or early in embryonic 
development affecting neuronal lineages. Therefore, characterising the extent of this neuronal 
mosaicism is challenging.
26
 
Single cell-based analysis of somatic retrotransposition events suggest retrotransposition 
frequencies of 0.2 to 16.3 new insertions per neuron depending on the brain region and type of 
analysis.
50-52
  Although the actual rate of somatic retrotransposition in neurons is still an area of 
controversy, somatic insertions have been validated and characterised, showing that the genome of 
an individual or groups of neurons can be altered by these elements. Even taking the lowest rate of 
0.2 per neuron would result in 20 billion unique insertions in the adult human brain.
53
 In the adult 
brain, somatic insertions are more likely to occur into expressed genes due to their open chromatin. 
It is hypothesised that a controlled level of somatic retrotransposition in neuronal genomes may be 
beneficial in generating diversity between neurons thus enabling individuals to respond to their 
environment and could be a mechanism involved in memory and learning.
27 49
 Conversely, increased 
non-LTR retrotransposon activation beyond what may be beneficial, and the misregulation of these 
mobile elements could contribute to neurodegeneration and cognitive decline. Changes to the 
chromatin structure and de-repression of retrotransposons during ageing has been associated with 
their increased transcript expression. This increase in retrotransposon mRNA expression and 
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evidence for mobilisation has been identified for non-LTR retrotransposons in replicatively senescent 
human cells (normal diploid fibroblasts), both LTR and non LTR retrotransposons in the ageing 
mouse (liver and muscle tissue) and LINE-like and LTR retrotransposons in the brain of Drosophila 
where it was linked to cognitive decline.
54-56
 Age is a risk factor for many neurodegenerative 
conditions and changes to retrotransposon regulation during ageing may be part of this increasing 
risk for disease. Although mRNA and retrotransposons encoded proteins have been shown to be 
upregulated in ALS, it has yet to be determined if there is an increase in somatic retrotransposition 
events in the brains of ALS patients and whether the site of insertion could affect the normal 
functioning of those neurons.  
 
SUMMARY 
ALS is thought to be a multistep process involving a complex interplay between germline genetic 
variation that defines the level of risk an individual is born with and subsequent modifiers, we are 
confronted with as we age, such as the environment, which determines whether an individual 
develops the disease or not. The presence or absence of retrotransposon insertions contributes 
extensively to germline genetic variation affecting the structure, splicing and expression of genes. To 
date, this type of genetic variation has not yet been addressed in ALS cohorts and should not be 
overlooked as a potential source of germline risk to the disease. The regulation of these 
retrotransposons is modified by age and in neurological disorders, including ALS, and can alter the 
genome of individual or groups of neurons in the adult brain. The changes in the regulation of 
retrotransposon insertions and the consequences of genomic alterations caused by somatic 
retrotransposon mobilisation could affect normal cellular function and even lead to cell death 
contributing to later steps of the disease development process. Further studies are required to fully 
investigate the exact role of retrotransposons and determine if there is a direct cause and effect 
relationship between retrotransposon activity or individual retrotransposon insertions and 
neurological diseases. Retrotransposons have the potential to be involved in multiple steps of the 
development of ALS from contributing to the missing heritability of the disease to neuronal 
dysfunction and degenerative processes.  
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Figure 1: Structure of transposable elements in the human genome. A) Structure of Hsmar-1, a 
member of the mariner-like DNA transposon superfamily. The human genome harbours inactive 
members of seven of the nine eukaryotic superfamilies of DNA transposons.
S33
 (TIR-terminal 
inverted repeat) B) Organisation of the retrotransposons HERV-K, LINE-1, Alu and SVA. An intact full 
length HERV-K provirus is ∼9.5 kb long, codes for group-specific antigen (Gag), protease (Pro), 
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polymerase (Pol) and envelope (Env) proteins and is flanked by ∼1kb long terminal repeats (LTRs) 
with the 5’LTR including the HERV-K promoter. A functional full length LINE-1 element is ∼6 kb in 
length, encodes three open reading frames (ORF0, ORF1 and ORF2) with ORF1 and ORF2 being 
separated by a 63bp noncoding spacer region. The 5’ untranslated region (5’UTR) harbours the 
endogenous LINE-1 promoter and an antisense promoter. The 3’ untranslated region (3’UTR) 
includes the transcriptional termination signal. Alu elements are primate specific short interspersed 
nuclear elements (SINEs) that are ∼280-300bp long and are composed of a 7SL-RNA derived left and 
right monomer separated by an A-rich connector (A5TACA6) and end in a poly A tail (An). The SVA 
element is a composite hominid specific retrotransposon containing a (CCCTCT)n hexamer repeat, an 
Alu-like region consisting of two antisense Alu fragments and an intervening unique sequence, a 
variable number of tandem repeats (VNTR) region, and a short interspersed element of retroviral 
origin (SINE-R) region. The length of an intact SVA can vary depending on the number of repeats 
present in the hexamer and VNTR domains and the length of the poly A-tail. LINE-1, Alu and SVA 
insertions are characterised by the hallmarks of LINE-1-mediated retrotransposition such as flanking 
variable target site duplications (TSDs, black triangles), polyA tails at their 3’ ends (An) and insertion 
at the consensus target sequence 5’-TTTT/AA-3’.  
 
Figure 2: The effects of LTR retrotransposon insertions on the host genome. Both intact full-length 
HERV proviruses and solo LTRs that are the result of recombination events can affect host gene 
expression. The mechanisms through which these insertions can act are outlined. A) LTR sequences 
contain regulatory domains to control the expression of the proviral HERV insertions and may 
become exapted as a novel promoter controlling host gene expression often in a tissue specific 
manner. B) The LTRs of HERVs contain binding sites for transcription factors that can either act to 
enhance or repress host gene expression depending on the protein complexes bound. C) A small 
number of HERV insertions retain coding capacity and specific insertions play an important role in 
humans, for example the Env protein of a HERV-W insertion is involved in human placental 
morphogenesis and the formation of the syncytiotrophoblast. D) The full-length HERV provirus or 
solo LTRs in an intron can result in alternative splicing of the host gene due to splice sites present in 
the HERV sequences. E) Full-length HERV provirus or solo LTRs located downstream of a host gene 
can promote the expression of antisense transcripts of this gene. F) Sequence similarities between 
HERV LTRs across the genome provide binding sites for the same transcription factors allowing for 
the regulation of a network of genes. G) HERV-encoded polyA signals that are located in introns can 
cause premature termination or pausing of transcription. H) DNA methylation and repressive histone 
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modifications (e.g. H3K9me3) act to silence HERV expression and can impact on neighbouring gene 
expression. This figure was compiled from references 15, S9 and S34. 
 
Figure 3: Schematic of the endogenous LINE-1 retrotransposition cycle. An intact, full-length LINE-1 
source element on chromosome A is transcribed by RNA Polymerase II. The resulting bicistronic 
mRNA is exported into the cytoplasm where translation of the encoded open reading frames (ORFs) 
occurs. Acting in cis: ORF1p and ORF2p exhibit a cis-preference for their own mRNA molecule. A 
multitude of ORF1p trimers and as few as one copy of ORF2p associate with their encoding RNA to 
form an LINE-1 ribonucleoprotein (L1 RNP) particle. Either the entire RNP or RNP components enter 
the nucleus where LINE-1 endonuclease (EN) activity nicks the genomic DNA of chromosome B at the 
LINE-1 consensus 5’-TTTT/A-3’, exposing a 3’ hydroxyl residue from which the LINE-1 reverse 
transcriptase (RT) initiates target site-primed reverse transcription (TPRT) of the associated LINE-1 
mRNA. Processes leading to second-strand cleavage, and second strand-complementary DNA (cDNA) 
synthesis are still unclear. TPRT results in target site duplication-flanked LINE-1 de novo insertions 
which are seldom full-length and usually 5’-truncated. Acting in trans: Occasionally, LINE-1-encoded 
ORF1p and ORF2p bind Alu RNA, SVA mRNA or cellular host gene-encoded RNA-Polymerase II 
mRNAs in the cytoplasm, form RNPs with these RNAs and mediate their trans-mobilisation by TPRT. 
The figure has been adapted from multiple reviews. 
31
 
S18 S35
 (ORF1p – protein encoded by ORF1 of 
LINE-1, ORF2p – protein encoded by ORF2 of LINE-1) 
Figure 4: The effects of non-LTR retrotransposon insertions on host gene expression. Non-LTR 
retrotransposon insertions can affect gene expression through multiple mechanisms and the major 
mechanisms are outlined. A) The control of host gene expression by sense and/or antisense 
promoters of neighbouring non-LTR retrotransposon insertions has been reported for LINE-1 and Alu 
elements
16
 and the initial 328 bp of a specific subtype of SVAs have been reported to harbour 
promoter activity.
S36
 Transcriptional start sites have been identified within LINE-1, Alu and SVA 
sequences.
S37 S38
 B) LINE-1, Alu and SVA sequences contain binding sites for transcription factors that 
can have either positive or negative regulatory effects on the expression of neighbouring host genes 
depending on the protein complexes bound.
S39
 C) LINE-1, Alu and SVA insertions into exons can 
cause loss of function mutations.
15
 D) Splice sites within LINE-1, Alu and SVA insertions residing in 
introns can result in new exons within host genes and alternative splicing.
15
 E) When two Alu repeats 
are inserted in the opposite orientation in close proximity, base pairing between the two repeats can 
occur in the mRNA forming double stranded RNA. Adenosine deaminases can bind to the double 
stranded RNA and deaminate adenosine to inosine (A to I editing) affecting transcript stability. As 
inosine is recognised by the translational and splicing machinery as guanosine, this RNA editing could 
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lead to an amino acid substitution (if occurs in the coding sequence), alternative splicing or 
modification of microRNA binding.
S40
 F) The adenosine-rich nature of LINE-1, Alu and SVA transcripts 
can introduce premature polyadenylation and/or RNA polymerase II transcriptional pause sites into 
genes, thereby resulting in termination of transcription within the retrotransposons sequence or 
reducing their expression.
S38 S41
 G) Epigenetic alterations at the integration site of a new 
retrotransposon insertion can restrict retrotransposon expression and include DNA methylation 
(LINE-1, Alu and SVAs contain multiple CpG sites) and heterochromatin formation which can also 
lead to the repression of neighbouring genes.
53
 H) Full-length LINE-1 insertions that inserted in the 
antisense orientation into an intron of a cellular gene can split the gene’s transcript into two smaller 
transcripts through a mechanism known as gene breaking.
S42
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Figure 1: Structure of transposable elements in the human genome  
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Figure 2: The effects of LTR retrotransposon insertions on the host genome.  
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Figure 3: Schematic of the endogenous LINE-1 retrotransposition cycle  
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Figure 4: The effects of non-LTR retrotransposon insertions on host gene expression.  
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